Open AccessEvaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors
Author(s) -
Muthiah Vaduganathan,
Robert A. Harrington,
Gregg W. Stone,
Efthymios Deliargyris,
Philippe Gabríel Steg,
C. Michael Gibson,
Christian W. Hamm,
Matthew J. Price,
Alberto Menozzi,
Jayne Prats,
Steven Elkin,
Kenneth W. Mahaffey,
Harvey D. White,
Deepak L. Bhatt
Publication year - 2016
Publication title -
jama cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.108
H-Index - 63
eISSN - 2380-6591
pISSN - 2380-6583
DOI - 10.1001/jamacardio.2016.4556
Subject(s) - cangrelor , medicine , timi , conventional pci , percutaneous coronary intervention , clopidogrel , ticlopidine , cardiology , platelet aggregation inhibitor , myocardial infarction , p2y12 , anesthesia , aspirin
In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom